Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.40 |
| ▸ | AURKA | O14965 | 3/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2182306 | 1.00 | EGFR (0.40) | EGFRAURKACHEK1MAPTLMNA | |
| SCHEMBL2178672 | 0.89 | EGFR (0.44) | EGFRAURKACHEK1 | |
| SCHEMBL13093741 | 0.88 | AURKA (0.37) | EGFRAURKACHEK1MAPTLMNA | |
| SCHEMBL13093740 | 0.87 | AURKA (0.38) | EGFRAURKACHEK1 | |
| SCHEMBL3067590 | 0.86 | AURKA (0.35) | EGFRAURKACHEK1 | |
| SCHEMBL3067592 | 0.86 | AURKA (0.35) | EGFRAURKACHEK1 | |
| SCHEMBL6750681 | 0.85 | KDM4E (0.49) | EGFRAURKACHEK1MAPTPOLB | |
| SCHEMBL6750654 | 0.85 | KDM4E (0.49) | EGFRAURKACHEK1MAPTPOLB | |
| SCHEMBL4527244 | 0.85 | KDM4E (0.49) | EGFRAURKACHEK1MAPTPOLB | |
| SCHEMBL13093742 | 0.84 | AURKA (0.36) | EGFRAURKACHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166163-A1 | SUBSTITUTED FUROPYRIMIDINES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-07-07 | — | — | US | disclosed |
| US-20110166163-A1 | SUBSTITUTED FUROPYRIMIDINES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-07-07 | — | — | US | disclosed |
| WO-2008155016-A1 | SUBSTITUTED FUROPYRIMIDINES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166163-A1 | SUBSTITUTED FUROPYRIMIDINES AND USE THEREOF | DPYD, TPMT, TYMP | EGFR 4267/4885AURKA 2987/4885CHEK1 800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.